Efficacy and safety of venetoclax combined with azacitidine for treatment of high-risk myelodysplastic syndromes
10.3760/cma.j.cn115356-20230926-00044
- VernacularTitle:维奈克拉联合阿扎胞苷治疗高危骨髓增生异常综合征的效果及安全性
- Author:
Gongai WANG
1
;
Yanyan LIANG
;
Yongtian ZHANG
;
Yuanyuan ZHANG
;
Haiguo ZHANG
;
Yunliang HAO
Author Information
1. 济宁市第一人民医院血液内科，济宁 272100
- Keywords:
Myelodysplastic syndromes;
Drug therapy, combination;
Venetoclax;
Azacitidine
- From:
Journal of Leukemia & Lymphoma
2024;33(6):349-351
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the clinical effect and safety of venetoclax combined with azacitidine for high-risk myelodysplastic syndromes (MDS).Methods:A retrospective case series study was conducted. The clinical data of 48 patients with high-risk MDS in Jining No.1 People's Hospital from January 2020 to May 2023 were collected, and all patients were divided into the control group (20 cases) and the test group (28 cases) according to medications. The control group was treated with azacitidine alone, and the test group was treated with venetoclax combined with azacitidine regimen. The total effective rate and adverse reactions of the 2 groups were compared after 3 courses of treatment.Results:Among 48 patients, 30 cases were male and 18 cases were females; the median onset age [ M ( Q1, Q3)] was 62 years (54 years, 75 years). There were no statistically significant differences in gender, age, white blood cell count, neutrophil count, hemoglobin, platelet count, bone marrow original cells proportion between the 2 groups (all P>0.05). After 3 courses of treatment, the total effective rate in the test group was 75% (22/28), and the rate in the control group was 45% (9/20), and there was a statistically significant difference between the two groups ( χ2 = 5.74, P<0.05). The incidence of grade 3 and the above adverse reactions in the control group and the test group was 25% (5/20), 54% (15/28), respectively, and the difference was statistically significant ( χ2 = 1.62, P>0.05). Conclusions:Venetoclax combined with azacitidine regimen for high-risk MDS can improve the clinical efficacy, and the adverse reactions can be tolerated.
